KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for TherapeuticsMD (TXMD) over the last 7 years, with Q3 2025 value amounting to $5000.0.

  • TherapeuticsMD's Gains from Sales and Divestitures fell 8684.21% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5000.0, marking a year-over-year decrease of 8684.21%. This contributed to the annual value of $38000.0 for FY2024, which is 7888.89% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Gains from Sales and Divestitures is $5000.0, which was down 8684.21% from $5000.0 recorded in Q2 2025.
  • TherapeuticsMD's Gains from Sales and Divestitures' 5-year high stood at $2.0 million during Q3 2021, with a 5-year trough of $7.0 in Q1 2024.
  • For the 5-year period, TherapeuticsMD's Gains from Sales and Divestitures averaged around $240088.9, with its median value being $38000.0 (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Gains from Sales and Divestitures plummeted by 9968.25% in 2022, and later skyrocketed by 5494587.16% in 2023.
  • Over the past 5 years, TherapeuticsMD's Gains from Sales and Divestitures (Quarter) stood at $103000.0 in 2021, then tumbled by 99.68% to $327.0 in 2022, then soared by 54945.87% to $180000.0 in 2023, then crashed by 78.89% to $38000.0 in 2024, then crashed by 86.84% to $5000.0 in 2025.
  • Its Gains from Sales and Divestitures was $5000.0 in Q3 2025, compared to $5000.0 in Q2 2025 and $2000.0 in Q1 2025.